Designing Novel Antibodies with AI: Discovering Candidates by Combining Donga ST’s ADC Technology

Validating the Potential for ADC Development Targeting Previously Untreated Novel Targets

Donga ST announced on October 1 that it has signed a joint research agreement with AI drug discovery company Galaxy to develop new antibody-drug conjugates (ADCs).


This collaborative research aims to discover promising ADC drug candidates targeting novel targets for which no existing treatments currently exist, by combining Donga ST's capabilities in ADC development with Galaxy’s AI-based antibody design technology.


Donga ST and Galaxy logo images. Donga ST / Galaxy

Donga ST and Galaxy logo images. Donga ST / Galaxy

View original image

An ADC is a therapeutic that links a payload, which is a drug that kills cancer cells, to an antibody capable of recognizing a specific target via a linker. Among these components, the antibody plays a key role in determining how selectively the ADC finds cancer cells and delivers the drug payload.


Galaxy designs antibody candidates for ADCs using its AI protein design platform, GalaxyDesign, via a de novo approach. This involves analyzing the structure and function of target proteins to identify novel antibody candidates with properties suitable for drug development.


Donga ST will evaluate the applicability of the antibody candidates designed by Galaxy to ADCs and is set to develop subsequent candidates by leveraging its own accumulated ADC technology and its expertise in linker and payload development.


Through this joint research, the two companies aim to validate the potential for developing ADCs targeting novel, previously untreated targets and to develop the identified candidates into best-in-class new drugs.


Galaxy is an AI drug development company that designs proteins, including antibodies, based on its AI protein design platform, GalaxyDesign. Its technology enables the analysis of protein structures and interactions to design proteins tailored to disease targets and to identify candidates with a range of properties required for therapeutic development.


Park Taeyong, CEO of Galaxy, said, "This collaboration demonstrates that Galaxy’s de novo antibody design technology can be applied to complex modalities such as ADCs. By utilizing GalaxyDesign, we aim to discover antibody candidates that are difficult to obtain with conventional experiment-based discovery methods and contribute to differentiated new drug development."



Oh Yoonseok, Vice President of Donga ST, stated, "By incorporating AI-based antibody design technology into ADC research and development, we expect to more systematically verify the development potential for novel targets. Leveraging Donga ST’s accumulated ADC development capabilities, we will secure competitive candidates and advance them into best-in-class new drugs."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing